NCT02413736View on ClinicalTrials.gov

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

255

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2033

Conditions

Sarcoma

Interventions

DRUG

Imatinib

Imatinib 400 mg/day

Trial Locations (1)

00029

Helsinki University Central Hospital, Helsinki

All Listed Sponsors

collaborator

Scandinavian Sarcoma Group

OTHER

lead

Heikki Joensuu

OTHER